Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion type Assertion NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_head.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion description "[Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_provenance.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion evidence source_evidence_literature NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_provenance.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion SIO_000772 24555920 NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_provenance.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion wasDerivedFrom befree-20150227 NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_provenance.
- NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_assertion wasGeneratedBy ECO_0000203 NP772236.RAXYE6fVgd0SP7HwhONvw0KlvbtK8b09yT8GSpePITWl0130_provenance.